Background: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population.

The following is a summary of “Impact of AKI on metabolic compensation for respiratory acidosis in ICU patients with AECOPD,” ...

• Fenoldopam (a medicine that rapidly widens and relaxes blood vessels) probably reduces the risk of developing acute kidney injury (AKI) (a condition where the kidneys suddenly lose their ability to ...

Drug-induced AKI (acute kidney injury) is common and may include medications not previously known to exhibit this safety signal.

A new study published in the International Journal of General Medicine found that a severe vitamin D deficit (<10 ng/mL) ...

Bone fracture may be among the adverse outcomes of acute kidney injury (AKI), investigators suggest ... The finding nonetheless suggests that patients with even mild AKI need to be monitored. The ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to ...

Charting, Price Performance, News & Related Contracts.

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute ...

Reports from the health department highlighted an alarming rise in maternal deaths at the Ballari district hospital between ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...